On the basis of previous reports describing increased HER3 expression in response to PI3K inhibition in the PTEN-null cell line LNCaP (25), we aimed to expand the analysis to HER2, having previously shown that HER2-HER3 dimerization is crucial for cancer progression and patient stratification (24). Here, ERBB2 is linked to cancer.